Wei Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Shi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Hai Qian
China Pharmaceutical University
2 shared publications - Da Fu
Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Dan Wang
Center of Drug Discovery State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 211198 P. R. China
1 shared publicationDongbo Tang
Center of Drug Discovery State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 211198 P. R. China
1 shared publicationFanglian Chi
Centre of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, PR China
1 shared publication- Gao-Ren Wang
Department of Radiotherapy Nantong Tumor Hospital Nantong China
1 shared publication
Latest Publications
- 21 July 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (15) , e202500296
Rational Design and Bioactive Screening of Peptide Inhibitors Targeting Host–Pathogen Interactions in Severe Fever with Thrombocytopenia Syndrome Virus
Severe fever with thrombocytopenia syndrome virus (SFTSV) poses a significant threat to public health, with limited therapeutic options available. This study focuses on the rational design and screening of peptide inhibitors targeting host–pathogen interactions, specifically between the viral Gn glycoprotein and key host cell receptors, DC‐SIGN and NMMHC‐IIA. By employing molecular dynamics simulations, alanine scanning, and peptide docking techniques, peptides were designed to disrupt these protein–protein interactions. Among the synthesized candidates, peptides II‐1 and II‐4 demonstrate potent inhibitory activity against SFTSV infection, with reduced TCID50 values in cellular assays and displayed exceptional affinity (KD = 7.381 × 10−8 M, 1.439 × 10−8 M), These peptides also exhibit low cytotoxicity and hemolytic toxicity, highlighting their safety profile. Molecular dynamics simulations confirm strong binding affinities for these peptides, underpinned by stable hydrogen bonding interactions. This research provides a promising platform for developing peptide‐based therapeutics targeting SFTSV, paving the way for further preclinical evaluation and clinical applications.
- 21 July 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (15) , e202500296
Rational Design and Bioactive Screening of Peptide Inhibitors Targeting Host–Pathogen Interactions in Severe Fever with Thrombocytopenia Syndrome Virus
Severe fever with thrombocytopenia syndrome virus (SFTSV) poses a significant threat to public health, with limited therapeutic options available. This study focuses on the rational design and screening of peptide inhibitors targeting host–pathogen interactions, specifically between the viral Gn glycoprotein and key host cell receptors, DC‐SIGN and NMMHC‐IIA. By employing molecular dynamics simulations, alanine scanning, and peptide docking techniques, peptides were designed to disrupt these protein–protein interactions. Among the synthesized candidates, peptides II‐1 and II‐4 demonstrate potent inhibitory activity against SFTSV infection, with reduced TCID50 values in cellular assays and displayed exceptional affinity (KD = 7.381 × 10−8 M, 1.439 × 10−8 M), These peptides also exhibit low cytotoxicity and hemolytic toxicity, highlighting their safety profile. Molecular dynamics simulations confirm strong binding affinities for these peptides, underpinned by stable hydrogen bonding interactions. This research provides a promising platform for developing peptide‐based therapeutics targeting SFTSV, paving the way for further preclinical evaluation and clinical applications.
- 20 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 231, 114142
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
- 20 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 231, 114142
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
- 8 May 2020
- Published by Springer Nature in Biologia
- Vol. 75 (7) , 997-1007
Serotonin-induced miR-221/222 contribute to the activation of hepatic stellate cells
- 8 May 2020
- Published by Springer Nature in Biologia
- Vol. 75 (7) , 997-1007
Serotonin-induced miR-221/222 contribute to the activation of hepatic stellate cells